Myelodysplastic Syndrome (MDS)
Drugs Market
Myelodysplastic Syndrome (MDS) Drugs Market
Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Myelodysplastic Syndrome (MDS) Drugs Market Size and Growth
The global Myelodysplastic Syndrome (MDS) Drugs market is projected to reach a value of $1.5 billion by 2026, with a CAGR of 7.8% during the forecast period. The market is driven by increasing prevalence of MDS and advancements in drug development. Key players include Celgene Corporation, Novartis AG, and Amgen Inc.
Sample Report
Request
Companies Covered (Covid 19 Impact Covered)
◍ Celgene
◍ Amgen
◍ Otsuka
◍ Takeda
The competitive landscape of the Myelodysplastic Syndrome (MDS) Drugs Market includes prominent companies such as Celgene, Amgen, Otsuka, and Takeda. These companies develop and market drugs for the treatment of MDS, contributing to the growth of the market.
- Celgene: $18.7 billion
- Amgen: $23.7 billion
- Otsuka: $11.5 billion
- Takeda: $30.1 billion
Request Sample Report
Market Segmentation
By Application
◍ Original
◍ Generics
By Product
◍ Hypomethylating Agents
◍ Immunomodulatory Drugs
◍ Anti-anemics
Request Sample Report
THANK YOU Email : sales@reportprime.com USA : +1 507 500 7209 Website : https://www.reportprime.com/ Request Sample Report Contact US Our Clients